Effect of the rectal administration of indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes;Efecto de la administración de indometacina rectal sobre los niveles séricos de amilasa posteriores a colangiopancreatografía retrógrada endoscópica y su impacto en la aparición de episodios de pancreatitis secundaria

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 6, 2007, Pages 330-336

  Montano Loza A ^a   Rodriguez Lomeli X ^a   Garcia Correa J E ^a   Davalos Cobian C ^a   Cervantes Guevara, G ^b   Medrano Munoz F ^c   Fuentes Orozco, C ^c   González Ojeda, Alejandro ^c,d  

^a CMNO IMSS

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d NONE   (Mexico)

Author keywords

Acute pancreatitis; Endoscopic retrograde cholangiopancreatography; Hyperamylasemia; Indomethacin

Indexed keywords

GLYCEROL; INDOMETACIN; AMYLASE; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERAMYLASEMIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ACUTE DISEASE; BILIARY TRACT DISEASE; BLOOD; MIDDLE AGED; PANCREATITIS; PREMEDICATION; RECTAL DRUG ADMINISTRATION; SINGLE BLIND PROCEDURE;

ACUTE DISEASE; ADMINISTRATION, RECTAL; ADULT; AGED; AMYLASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILIARY TRACT DISEASES; BIOLOGICAL MARKERS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; PANCREATITIS; PREMEDICATION; SINGLE-BLIND METHOD;

EID: 35848938503     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Nebel OT, Silvis SE, Rogers G, Sugawa C, Mandelstam P. Complications associated with endoscopic retrograde cholangiopancreatography. Results of the 1974 A/S/G/E survey. Gastrointest Endosc 1975; 22: 34-6.
2. LaFerla G, Gordon S, Archibald M, Murray WR. Hyperamilasaemia and acute pancreatitis following endoscopic retrograde cholangiography. Pancreas 1986; 1: 160-3.
3. De Palma GD, Catanzano C. Use of corticosteroids in the prevention of post-ERCP pancreatitis: Results of a controlled prospective study. Am J Gastroenterol 1999; 94: 982-5.
4. Rabenstein T, Hahn EG. Post-ERCP pancreatitis: New momentum. Endoscopy 2002; 34: 325-9.
5. García Cano Lizcano J, González Martín JA, Morillas Ariño J, Pérez Sola A. Complications of endoscopic retrograde cholangiopancreatography. A study in a small ERCP Unit. Rev Esp Enferm Dig 2004; 96: 163-73.
6. Vaira D, D'Anna L, Ainley C, Dowsett J, Williams S, Baillie J, et al. Endoscopic sphincterotomy in 1000 consecutive patients. Lancet 1989; 2: 431-4.
7. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-34.
8. Barthet M, Lesavre N, Desjeux A, Gasmi M, Berthezene P, Berdah S, et al. Complications of endoscopic sphincterotomy: Results from a single tertiary referral center. Endoscopy 2002; 34: 991-7.
9. Rodríguez Muñoz S. Towards safer ERCP: Selection, experience and prophylaxis. Rev Esp Enferm Dig 2004; 96: 155-62.
10. Podolsky I, Haber GB, Kortan P, Gray R. Risk factors for pancreatitis following ERCP. A prospective study (abstr). Am J Gastroenterol 1987; 82: 972A.
11. Bilbao MK, Dotter CT, Lee TG, Katon RM. Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases. Gastroenterology 1976; 70: 314-20.
12. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-18.
13. Messmann H, Vogt W, Holstege A, Lock G, Heinisch A, von Furstenberg A, et al. Post ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997; 40: 80-5.
14. Karne S, Gorelick FS. Etiopathogenesis of acute pancreatitis. Surg Clin North Am 1999; 79: 699-710.
15. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190: 117-25.
16. Silvis SE, Vennes JA. The role of glucagon in endoscopic cholangiopancreatography. Gastrointest Endosc 1975; 21: 162-3.
17. Odes HS, Novis BN, Bank S. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 1977; 16: 180-4.
18. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54: 105-11.
19. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatine analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994; 26: 715-8.
20. Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, et al. Pretreatment with methylprednisolone to prevent ERCP induced pancreatitis: A randomized, multicenter, placebo controlled clinical trial. Am J Gastroenterol 1998; 93: 61-5.
21. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: A meta-analysis. Gastrointest Endosc 2000; 51: 1-7.
22. Gross V, Leser HG, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines: New aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40: 522-30.
23. Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997; 57: 401-7.
24. Wildenhain PM, Melhem MF, Birsic WI, Sell HW, Rao KN. Acute hemorrhagic pancreatitis in mice: Improved survival after indomethacin administration. Digestion 1989; 44: 41-51.
25. Mejía Aranguré JM, Fajardo Gutiérrez A, Gómez Delgado A, Cuevas Orióstegui ML, Hernández Hernández DM, Garduño Espinosa J, et al. El tamaño de la muestra: un enfoque práctico en la investigación clínica. Bol Med Hosp Infant Mex 1995; 52: 381-90.
26. Osvaldt AB, Viero P, Borges da Costa MS, Wendt LR, Bersch VP, et al. Evaluation of Ranson, Glasgow, APACHE-II, and APACHE-O criteria to predict severity in acute biliary pancreatitis. Int Surg 2001; 86: 158-61.
27. Montaño Loza A, García Correa J, González Ojeda A, Fuentes Orozco C, Davalos Cobián C, Rodríguez Lomelí X. Prevención de hiperamilasemia y pancreatitis posterior a colangiografía retrógrada endoscópica con la administración rectal de indometacina. Rev Gastroenterol Mex 2006; 71: 262-8.
28. Insel PA. Analgesic, antipyretic and anti-inflammatory agents and drugs employed in the treatment of Gout. In Goodman and Gilman. The Pharmacological basis of therapeutics. 9th ed. Nashville, Tennessee: McGraw Hill 1996. p. 643-5.
29. Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy 2005; 25: 18-25.
30. Italian Digestive Endoscopy Group: Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996; 335: 919-23.
31. Ebbehoj N, Friis J, Svendsen LB, Bulow S, Madsen P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol 1985; 20: 798-800.
32. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-91.
33. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Bernardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10.
34. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study. Am J Gastroenterol 2001; 96: 417- 23.
35. Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, et al. Interleukin-10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498-505.
36. Dumot JA, Conwell DL, Zuccaro G, Vargo JJ, Shay SS, Easley KA, et al. A randomized double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96: 2098-102.
37. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001; 88: 1178-82.
38. Moreto M, Zaballa M, Casado I, Merino O, Rueda M, Ramírez Z, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc 2003; 57: 1-7.
39. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, et al. Complications of endoscopic sphincterotomy: Can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55: 476-83.
40. Frank CD, Adler DG. Post-ERCP pancreatitis and its prevention. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 680-8.
41. Memis D, Akalin E, Yüvel T. Indomethacin-induced pancreatitis. A case report. JOP 2005; 6: 344-7.
42. Mahjoub W, Jarboui S, Ben Moussa M, Abdesselem MM, Zaouche A. Indomethacin-induced pancreatitis; a second case report. JOP 2006; 7: 321-3.
43. Trivedi ChD, Pitchumoni CS. Drug-induced pancreatitis. An update. J Clin Gastroenterol 2005; 39: 709-16.